Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/EUCTR2020-003140-83-CZ
EUCTR2020-003140-83-CZActive, not recruitingPhase 1

A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of NBI-921352 as Adjunctive Therapy in Subjects with SCN8A Developmental and Epileptic Encephalopathy Syndrome (SCN8A-DEE)

eurocrine Biosciences, Inc.0 sites60 target enrollmentStarted: September 13, 2021Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Trial Snapshot

Phase
Phase 1
Status
Active, not recruiting
Sponsor
Enrollment
60
Study OverviewEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional clinical trial of medicinal product

Eligibility Criteria

Sex
All

Inclusion Criteria

  • •Be a male or female 12 to 21 years of age, inclusive.
  • •Have a diagnosis of SCN8A-DEE supported by both clinical and genetic findings
  • •Have on average at least 1 countable motor seizure per week and not be seizure-free for more than 20 consecutive days.
  • •Being treated with at least 1 other ASM, but no more than 4 ASMs.
  • •Have failed to achieve seizure freedom with at least 2 ASMs.
  • •Must be using a nocturnal alerting system or practice consistent with standards of care at the time of screening and continue to use this for the duration of the study.
  • •Must have an adequate rescue medication regimen per the investigator’s judgment in place at the time of screening and for the duration of the study.
  • •Have a body weight of at least 10 kg
  • •The subject's parent/caregiver is able to accurately identify seizure types, especially countable motor seizures and is able to complete seizure diary
  • •Are the trial subjects under 18? yes
  • •Number of subjects for this age range: 23
  • •F.1.2 Adults (18-64 years) yes
  • •F.1.2.1 Number of subjects for this age range 7
  • •F.1.3 Elderly (>=65 years) no
  • •F.1.3.1 Number of subjects for this age range

Exclusion Criteria

  • •Have previously been enrolled in this study and received blinded treatment.
  • •Have participated in an interventional clinical trial <30 days prior to screening.
  • •Have symptoms that would be more consistent with another epilepsy disorder such as Dravet syndrome (eg, fever-induced episodes of status epilepticus, frequent myoclonic seizures, worsening on sodium channel blockers, absence seizures with generalized spike-and-wave EEG as the sole seizure type).
  • •Are currently receiving cannabinoids or medical marijuana except Epidiolex/Epidyolex, unless approved by the Sponsor.
  • •Are currently taking systemic steroids (excluding inhaled medication for asthma treatments). If subject has received these medications in the past, must be off these medications for at least 3 months prior to the screening visit and these drugs may not be initiated during the duration of the study. Intermittent steroids to treat nonepilepsy related diseases (such as allergies or dermatological conditions) are not exclusionary.
  • •Have a history of moderate or severe head trauma or other neurological disorders or systemic medical diseases that are, in the investigator’s opinion, likely to affect nervous system functioning.
  • •Have a clinically significant medical condition or chronic disease that in the opinion of the investigator would preclude the subject from participating in and completing the study or that could confound interpretation of study outcome.
  • •Have clinically significant abnormal vital signs at the screening visit as determined by the investigator.
  • •Have one or more clinical laboratory test values outside the reference range, based on blood samples taken at the screening visit, that are of potential risk to the subject’s safety
  • •Have, at the screening visit, an ECG finding of a corrected QT interval using Fridericia’s formula (QTcF) >450 msec or presence of any significant cardiac abnormality.

Investigators

Sponsor
eurocrine Biosciences, Inc.

Similar Trials

Active, not recruiting
Phase 1
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of VIB7734 for the Treatment of Moderate to Severely Active Systemic Lupus Erythematosus
EUCTR2020-005528-12-ESViela Bio, Inc.195
Active, not recruiting
Phase 1
A clinical study to test the efficacy and safety of BMS-986165 in Subjects with Systemic Lupus Erythematosus.Systemic Lupus Erythematosus
EUCTR2017-001203-79-DEBristol-Myers Squibb International Corporation360
Active, not recruiting
Phase 1
Study to Evaluate NBI-921352 as Adjunctive Therapy in Subjects With SCN8A Developmental and Epileptic Encephalopathy Syndrome (SCN8A-DEE)SCN8A Developmental and Epileptic Encephalopathy Syndrome (SCN8A-DEE)MedDRA version: 20.0Level: PTClassification code 10077380Term: Epileptic encephalopathySystem Organ Class: 10029205 - Nervous system disorders
EUCTR2020-003140-83-BEeurocrine Biosciences, Inc.60
Active, not recruiting
Not Applicable
A study of tivozanib hydrochloride plus paclitaxel versus placebo plus paclitaxel in the treatment of breast cancerocally recurrent and/or metastatic triple negative breast cancerMedDRA version: 14.1Level: LLTClassification code 10006193Term: Breast cancer NOS recurrentSystem Organ Class: 100000004864MedDRA version: 14.1Level: LLTClassification code 10027475Term: Metastatic breast cancerSystem Organ Class: 100000004864
EUCTR2012-003507-35-ESAVEO Pharmaceuticals, Inc.147
Active, not recruiting
Phase 1
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of BMS-986165 in Subjects with Moderate to Severe Crohn's DiseaseCrohn's Disease
EUCTR2017-001976-48-DKBristol-Myers Squibb International Corporation240
A Phase 2 Randomized, Double-Blind,... | Clinical Trial